Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics

Gut Microbes

Volumn 5, Issue 2, 2014, Pages 233-238

  Haiser, Henry J ^a   Seim, Kristen L ^b   Balskus, Emily P ^b   Turnbaugh, Peter J ^a  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Digoxin; Eggerthella lenta; Gnotobiotics; Human microbiome; Metagenomics; Pharmacokinetics; RNA seq

Indexed keywords

BIOLOGICAL MARKER; DIGOXIN; DNA 16S;

ARTICLE; BACTERIUM ISOLATION; CHEMICAL STRUCTURE; DNA ISOLATION; DRUG INACTIVATION; DRUG METABOLISM; EGGERTHELLA LENTA; ENZYME ACTIVITY; GENE EXPRESSION; GNOTOBIOTICS; HUMAN; INTESTINE FLORA; METAGENOMICS; MICROBIAL DEGRADATION; MOLECULAR DYNAMICS; NONHUMAN; POLYMERASE CHAIN REACTION; RNA SEQUENCE; SEQUENCE HOMOLOGY; ACTINOBACTERIA; ANIMAL; GASTROINTESTINAL TRACT; GERMFREE ANIMAL; METABOLISM; MICROBIOLOGY; MOUSE; PHYSIOLOGY;

ACTINOBACTERIA; ANIMALS; DIGOXIN; GASTROINTESTINAL TRACT; GERM-FREE LIFE; HUMANS; MICE;

EID: 84899456016     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.4161/gmic.27915     Document Type: Article

References (40)

1. Holt R. The bacterial degradation of chloramphenicol. Lancet 1967; 1: 1259-60; PMID: 4165044; http://dx. doi. org/10. 1016/S0140-6736(67)92720-1.
2. Gingell R, Bridges JW, Williams RT. Gut flora and the metabolism of prontosils in the rat. Biochem J 1969; 114: 5P-6P; PMID: 5810066.
3. Scheline RR. The metabolism of drugs and other organic compounds by the intestinal microflora. Acta Pharmacol Toxicol (Copenh) 1968; 26: 332-42; PMID: 5755481; http://dx. doi. org/10. 1111/j. 1600-0773. 1968. tb00453. x.
4. Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 2005; 3: 431-8; PMID: 15821725; http://dx. doi. org/10. 1038/nrmicro1152.
5. Holmes E, Kinross J, Gibson GR, Burcelin R, Jia W, Pettersson S, Nicholson JK. Therapeutic modulation of microbiota-host metabolic interactions. Sci Transl Med 2012; 4: rv6; PMID: 22674556; http://dx. doi. org/10. 1126/scitranslmed. 3004244.
6. Haiser HJ, Turnbaugh PJ. Is it time for a metagenomic basis of therapeutics? Science 2012; 336: 1253-5; PMID: 22674325; http://dx. doi. org/10. 1126/science. 1224396.
7. Wallace BD, Redinbo MR. The human microbiome is a source of therapeutic drug targets. Curr Opin Chem Biol 2013; 17: 379-84; PMID: 23680493; http://dx. doi. org/10. 1016/j. cbpa. 2013. 04. 011.
8. Haiser HJ, Turnbaugh PJ. Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res 2013; 69: 21-31; PMID: 22902524; http://dx. doi. org/10. 1016/j. phrs. 2012. 07. 009.
9. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330: 831-5; PMID: 21051639; http://dx. doi. org/10. 1126/science. 1191175.
10. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J Pharmacol Exp Ther 2012; 341: 447-54; PMID: 22328575; http://dx. doi. org/10. 1124/jpet. 111. 191122.
11. Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica 2014; 44: 28-35; PMID: 23829165; http://dx. doi. org/10. 3109/00498254. 2013. 811314.
12. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill, ed. 12, 2011.
13. Jacobs WA, Hoffmann A. The relationship between the structure and the biological action of the cardiac glucosides. J Biol Chem 1927; 74: 787-793.
14. Vick RL, Kahn JB Jr., Acheson GH. Effects of dihydro-ouabain, dihydrodigoxin and dihydrodigitoxin on the heart-lung preparation of the dog. J Pharmacol Exp Ther 1957; 121: 330-9; PMID: 13481854.
15. Herrmann I, Repke K. Transformation of cardenolides by microorganisms in the intestine. In: Schubert K, editor. Proceedings of the 2nd Symposium Über Biochemische Aspekte der Steroidforschung; 1968; Berlin, Germany. Berlin: Akademie-Verlag; 1969. p. 115-119.
16. Lindenbaum J, Rund DG, Butler VP Jr., Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981; 305: 789-94; PMID: 7266632; http://dx. doi. org/10. 1056/NEJM198110013051403.
17. Dobkin JF, Saha JR, Butler VP Jr., Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220: 325-7; PMID: 6836275; http://dx. doi. org/10. 1126/science. 6836275.
18. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 2013; 341: 295-8; PMID: 23869020; http://dx. doi. org/10. 1126/science. 1235872.
19. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-402; PMID: 9254694; http://dx. doi. org/10. 1093/nar/25. 17. 3389.
20. Söding J, Biegert A, Lupas AN. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res 2005; 33: W244-8; PMID: 15980461; http://dx. doi. org/10. 1093/nar/gki408.
21. Rodrigues ML, Oliveira T, Matias PM, Martins IC, Valente FM, Pereira IA, Archer M. Crystallization and preliminary structure determination of the membrane-bound complex cytochrome c nitrite reductase from Desulfovibrio vulgaris Hildenborough. Acta Crystallogr Sect F Struct Biol Cryst Commun 2006; 62: 565-8; PMID: 16754983; http://dx. doi. org/10. 1107/S1744309106016629.
22. Bagrov AY, Shapiro JI. Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 2008; 4: 378-92; PMID: 18542120; http://dx. doi. org/10. 1038/ncpneph0848.
23. Qazzaz HM, Jortani SA, Poole JM, Valdes R Jr. Evidence for presence of a reduced form of digoxin-like immunoreactive factor (dihydro-DLIF) in mammalian tissues. Clin Chem 1996; 42: 1092-9; PMID: 8674194.
24. Mathan VI, Wiederman J, Dobkin JF, Lindenbaum J. Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora. Gut 1989; 30: 971-7; PMID: 2759492; http://dx. doi. org/10. 1136/gut. 30. 7. 971.
25. Morowitz MJ, Denef VJ, Costello EK, Thomas BC, Poroyko V, Relman DA, Banfield JF. Strain-resolved community genomic analysis of gut microbial colonization in a premature infant. Proc Natl Acad Sci U S A 2011; 108: 1128-33; PMID: 21191099; http://dx. doi. org/10. 1073/pnas. 1010992108.
26. Schloissnig S, Arumugam M, Sunagawa S, Mitreva M, Tap J, Zhu A, Waller A, Mende DR, Kultima JR, Martin J, et al. Genomic variation landscape of the human gut microbiome. Nature 2013; 493: 45-50; PMID: 23222524; http://dx. doi. org/10. 1038/nature11711.
27. Chen SL, Wu M, Henderson JP, Hooton TM, Hibbing ME, Hultgren SJ, Gordon JI. Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci Transl Med 2013; 5: 84ra60; PMID: 23658245; http://dx. doi. org/10. 1126/scitranslmed. 3005497.
28. Campia I, Gazzano E, Pescarmona G, Ghigo D, Bosia A, Riganti C. Digoxin and ouabain increase the synthesis of cholesterol in human liver cells. Cell Mol Life Sci 2009; 66: 1580-94; PMID: 19288057; http://dx. doi. org/10. 1007/s00018-009-9018-5.
29. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008; 105: 19579-86; PMID: 19020076; http://dx. doi. org/10. 1073/pnas. 0809763105.
30. Huh JR, Leung MW, Huang P, Ryan DA, Krout MR, Malapaka RR, Chow J, Manel N, Ciofani M, Kim SV, et al. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity. Nature 2011; 472: 486-90; PMID: 21441909; http://dx. doi. org/10. 1038/nature09978.
31. Sperry JF, Wilkins TD. Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol 1976; 127: 780-4; PMID: 182668.
32. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 2009; 1: ra14; PMID: 20368178; http://dx. doi. org/10. 1126/scitranslmed. 3000322.
33. Faith JJ, McNulty NP, Rey FE, Gordon JI. Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 2011; 333: 101-4; PMID: 21596954; http://dx. doi. org/10. 1126/science. 1206025.
34. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505: 559-63; PMID: 24336217; http://dx. doi. org/10. 1038/nature12820.
35. Westman EL, Canova MJ, Radhi IJ, Koteva K, Kireeva I, Waglechner N, Wright GD. Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol 2012; 19: 1255-64; PMID: 23102220; http://dx. doi. org/10. 1016/j. chembiol. 2012. 08. 011.
36. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013; 152: 39-50; PMID: 23332745; http://dx. doi. org/10. 1016/j. cell. 2012. 10. 052.
37. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008; 363: 1-25; PMID: 18682282; http://dx. doi. org/10. 1016/j. ijpharm. 2008. 07. 009.
38. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108(Suppl 1): 4554-61; PMID: 20847294; http://dx. doi. org/10. 1073/pnas. 1000087107.
39. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-70; PMID: 24264989; http://dx. doi. org/10. 1126/science. 1240527.
40. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-6; PMID: 24264990; http://dx. doi. org/10. 1126/science. 1240537.